Thu Sep 19 08:22:04 UTC 2024: ## Hepion Pharmaceuticals Short Interest Drops, Stock Trading Below 50-Day Moving Average

**New York, NY – September 19, 2024** – Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) saw a significant decrease in short interest during August, according to a report by MarketBeat News. As of August 31st, short interest totaled 75,700 shares, down 6.8% from the August 15th total of 81,200 shares. This translates to a short-interest ratio of 0.5 days, based on an average daily trading volume of 151,400 shares. Currently, 1.3% of the company’s shares are sold short.

HEPA opened at $0.68 on Thursday, with a market capitalization of $3.69 million. The stock’s P/E ratio is -0.07, and its beta stands at 1.85. HEPA’s 52-week low is $0.55, while its 52-week high is $6.14. The stock currently trades below both its 50-day moving average of $0.78 and its 200-day moving average of $1.32.

Hepion Pharmaceuticals, a biopharmaceutical company, is focused on developing drug therapy treatment for chronic liver diseases in the United States. Its primary product, Rencofilstat, is a cyclophilin inhibitor that has completed Phase 2a clinical trials targeting multiple pathological pathways involved in liver disease progression. Rencofilstat is currently in Phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH). Preclinical studies have shown Rencofilstat to reduce liver fibrosis, inflammation, tumor burden, and titers of various viruses, including hepatitis B, C, and D.

The company last reported its quarterly earnings on August 13th, reporting ($0.68) earnings per share (EPS) for the quarter.

**Disclaimer:** This news article is based on information provided by MarketBeat News and is intended for informational purposes only. It is not intended to be a source of investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence before making any investment decisions.

Read More